Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg 2006 Sep;192(3):344-54

Date

08/22/2006

Pubmed ID

16920429

DOI

10.1016/j.amjsurg.2006.04.009

Scopus ID

2-s2.0-33747143741   80 Citations

Abstract

BACKGROUND: Infection of intravascular or implanted biomedical devices often involves biofilm-forming staphylococci that are recalcitrant to antimicrobial therapy. The present study investigated the activity of 6 antimicrobial agents against biofilm-forming and non-biofilm-forming strains of staphylococci adherent to the surface of selected biomedical devices.

METHODS: Five clinical staphylococcal strains were selected for study in (1) antibiotic-lock model (ALM) and (b) vascular graft model (Dacron and expanded polytetrafluoroethylene [ePFTE]) devices. Test strains were inoculated for 30 minutes to stabilize microbial adherence and then exposed to antibiotic; the impact on bacterial adherence was assessed at 1, 2, 4, 7, and 10 days.

RESULTS: Regarding ALM, daptomycin and rifampin were effective at eradicating staphylococcal adherence by day 4 (P<.01); linezolid and gentamicin by day 7 (P<.01); vancomycin by day 7; and ceftriaxone failed to eradicate staphylococcal adherence in 4 of 5 strains by day 10. Regarding ePTFE, daptomycin and linezolid eradicated staphylococcal adherence by day 2 (P<.01); rifampin by day 4 (P<.01); vancomycin and gentamicin by day 7 (P<.01); and ceftriaxone failed to eliminate staphylococcal adherence in 3 of 5 strains by day 10. Regarding Dacron, daptomycin and rifampin eradicated adherent strains by day 4 (P<.01); linezolid by day 7 (P<.01), and vancomycin, gentamicin, and ceftriaxone decreased staphylococcal adherence by 90%, 95%, and 78%, respectively, by day 10.

COMMENTS: Daptomycin, rifampin, and linezolid demonstrated greater efficacy and speed in eradicating microbial adherence of staphylococcal isolates from selected devices compared with vancomycin, gentamicin, or ceftriaxone (P<.01). Further studies are warranted, however, to validate the clinical efficacy of daptomycin and linezolid in the treatment of biomedical device-associated infections.

Author List

Edmiston CE Jr, Goheen MP, Seabrook GR, Johnson CP, Lewis BD, Brown KR, Towne JB

Authors

Kellie R. Brown MD Professor in the Surgery department at Medical College of Wisconsin
Christopher P. Johnson MD Professor in the Surgery department at Medical College of Wisconsin
Brian D. Lewis MD Professor in the Surgery department at Medical College of Wisconsin
Gary R. Seabrook MD Chief, Professor in the Surgery department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Acetamides
Anti-Bacterial Agents
Biofilms
Blood Vessel Prosthesis
Ceftriaxone
Daptomycin
Gentamicins
Linezolid
Microbial Sensitivity Tests
Oxazolidinones
Rifampin
Staphylococcus
Vancomycin
jenkins-FCD Prod-398 336d56a365602aa89dcc112f077233607d6a5abc